Do analysts recommend IXHL or NGEN?

NervGen Pharma has a consensus target price of $18.00, suggesting a potential upside of 849.87%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Incannex Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 2.75

Which has higher valuation and earnings, IXHL or NGEN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incannex Healthcare N/A N/A -$46.88M -$1.55 N/A NervGen Pharma N/A N/A N/A N/A N/A

Is IXHL or NGEN more profitable?

NervGen Pharma's return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% NervGen Pharma N/A N/A N/A

Do analysts recommend TNYA or IXHL?

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 410.86%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Incannex Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TNYA or IXHL more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% Incannex Healthcare N/A -81.01% -76.11%

Do analysts prefer IXHL or KRRO?

Korro Bio has a consensus price target of $16.71, indicating a potential upside of 52.31%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Incannex Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Korro Bio 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 2.92

Which has stronger valuation & earnings, GALT or IXHL?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Incannex Healthcare N/A N/A -$46.88M -$1.55 N/A

Is GALT or IXHL more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Incannex Healthcare N/A -81.01% -76.11%

Do analysts rate PRQR or IXHL?

ProQR Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 399.66%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Incannex Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Incannex Healthcare (IXHL) Competitors

$3.08 +0.03 (+0.98%)

As of 02:30 PM Eastern

Compare

IXHL vs. NGEN, TNYA, KRRO, GALT, and PRQR

Should you buy Incannex Healthcare stock or one of its competitors? MarketBeat compares Incannex Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incannex Healthcare include NervGen Pharma (NGEN), Tenaya Therapeutics (TNYA), Korro Bio (KRRO), Galectin Therapeutics (GALT), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

How does Incannex Healthcare compare to NervGen Pharma?

Incannex Healthcare (NASDAQ:IXHL) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

NervGen Pharma's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
NervGen Pharma	N/A	N/A	N/A

In the previous week, NervGen Pharma had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for NervGen Pharma and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.89 beat NervGen Pharma's score of 0.66 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Very Positive
NervGen Pharma	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

0.4% of Incannex Healthcare shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NervGen Pharma has a consensus target price of $18.00, suggesting a potential upside of 849.87%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

NervGen Pharma beats Incannex Healthcare on 7 of the 9 factors compared between the two stocks.

How does Incannex Healthcare compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 410.86%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tenaya Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, meaning that its share price is 600% more volatile than the broader market.

In the previous week, Tenaya Therapeutics had 5 more articles in the media than Incannex Healthcare. MarketBeat recorded 6 mentions for Tenaya Therapeutics and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.89 beat Tenaya Therapeutics' score of 0.62 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Tenaya Therapeutics	Positive
Incannex Healthcare	Very Positive

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Incannex Healthcare has lower revenue, but higher earnings than Tenaya Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$225K	755.16	-$90.60M	-$0.47	N/A
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A

Tenaya Therapeutics' return on equity of -80.56% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Incannex Healthcare	N/A	-81.01%	-76.11%

Summary

Tenaya Therapeutics beats Incannex Healthcare on 12 of the 15 factors compared between the two stocks.

How does Incannex Healthcare compare to Korro Bio?

Incannex Healthcare (NASDAQ:IXHL) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Incannex Healthcare has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Incannex Healthcare's return on equity of -81.01% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Incannex Healthcare has a beta of 7, indicating that its share price is 600% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3, indicating that its share price is 200% more volatile than the broader market.

Korro Bio has a consensus price target of $16.71, indicating a potential upside of 52.31%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Incannex Healthcare has higher earnings, but lower revenue than Korro Bio. Incannex Healthcare is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A
Korro Bio	$6.39M	24.76	-$117.26M	-$11.67	N/A

In the previous week, Korro Bio had 16 more articles in the media than Incannex Healthcare. MarketBeat recorded 17 mentions for Korro Bio and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.89 beat Korro Bio's score of 0.88 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Very Positive
Korro Bio	Positive

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Korro Bio beats Incannex Healthcare on 10 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Galectin Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 366.10%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Galectin Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Galectin Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, meaning that its stock price is 600% more volatile than the broader market.

In the previous week, Galectin Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.89 beat Galectin Therapeutics' score of 0.27 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Neutral
Incannex Healthcare	Very Positive

Galectin Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Incannex Healthcare	N/A	-81.01%	-76.11%

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A

Summary

Galectin Therapeutics beats Incannex Healthcare on 9 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

ProQR Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 399.66%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ProQR Therapeutics has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, meaning that its share price is 600% more volatile than the broader market.

Incannex Healthcare has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.50	-$47.73M	-$0.50	N/A
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A

Incannex Healthcare has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Incannex Healthcare's return on equity of -81.01% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Incannex Healthcare	N/A	-81.01%	-76.11%

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ProQR Therapeutics had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for ProQR Therapeutics and 1 mentions for Incannex Healthcare. ProQR Therapeutics' average media sentiment score of 1.89 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
ProQR Therapeutics	Very Positive
Incannex Healthcare	Very Positive

Summary

ProQR Therapeutics beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.88M	$2.91B	$6.26B	$12.43B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-1.99	17.65	22.42	24.23
Price / Sales	N/A	479.58	548.01	125.38
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	1.49	3.85	9.82	6.71
Net Income	-$46.88M	$75.85M	$3.56B	$337.09M
7 Day Performance	-5.17%	-1.80%	-1.17%	0.63%
1 Month Performance	-32.26%	21.90%	3.71%	5.15%
1 Year Performance	-45.96%	21.81%	27.28%	34.36%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	1.0727 of 5 stars	$3.08 +1.0%	N/A	-49.0%	$36.85M	N/A	N/A	3	Positive News
NGEN NervGen Pharma	3.5551 of 5 stars	$2.08 flat	$18.00 +765.4%	N/A	$167.71M	N/A	N/A	N/A	Gap Up High Trading Volume
TNYA Tenaya Therapeutics	2.8051 of 5 stars	$0.77 flat	$4.00 +417.8%	+71.7%	$167.63M	N/A	N/A	110	News Coverage Gap Up
KRRO Korro Bio	3.3001 of 5 stars	$11.61 flat	$16.71 +44.0%	+1.9%	$167.45M	$6.39M	N/A	70	Trending News Insider Trade Analyst Revision High Trading Volume
GALT Galectin Therapeutics	2.1983 of 5 stars	$2.50 flat	$11.00 +340.0%	+87.6%	$164.64M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. NGEN, TNYA, KRRO, GALT, and PRQR

How does Incannex Healthcare compare to NervGen Pharma?

Summary

How does Incannex Healthcare compare to Tenaya Therapeutics?

Summary

How does Incannex Healthcare compare to Korro Bio?

Summary

How does Incannex Healthcare compare to Galectin Therapeutics?

Summary

How does Incannex Healthcare compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. NGEN, TNYA, KRRO, GALT, and PRQR

How does Incannex Healthcare compare to NervGen Pharma?

Is IXHL or NGEN more profitable?

Does the media favor IXHL or NGEN?

Which has higher valuation and earnings, IXHL or NGEN?

Do insiders and institutionals hold more shares of IXHL or NGEN?

Do analysts recommend IXHL or NGEN?

Summary

How does Incannex Healthcare compare to Tenaya Therapeutics?

Do analysts recommend TNYA or IXHL?

Which has more volatility & risk, TNYA or IXHL?

Does the media refer more to TNYA or IXHL?

Do insiders and institutionals have more ownership in TNYA or IXHL?

Which has stronger valuation and earnings, TNYA or IXHL?

Is TNYA or IXHL more profitable?

Summary

How does Incannex Healthcare compare to Korro Bio?

Is IXHL or KRRO more profitable?

Which has more volatility and risk, IXHL or KRRO?

Do analysts prefer IXHL or KRRO?

Which has stronger valuation & earnings, IXHL or KRRO?

Does the media favor IXHL or KRRO?

Do insiders and institutionals believe in IXHL or KRRO?

Summary

How does Incannex Healthcare compare to Galectin Therapeutics?

Do analysts prefer GALT or IXHL?

Do insiders and institutionals have more ownership in GALT or IXHL?

Which has more risk & volatility, GALT or IXHL?

Does the media refer more to GALT or IXHL?

Is GALT or IXHL more profitable?

Which has stronger valuation & earnings, GALT or IXHL?

Summary

How does Incannex Healthcare compare to ProQR Therapeutics?

Do analysts rate PRQR or IXHL?

Which has more volatility & risk, PRQR or IXHL?

Which has higher valuation & earnings, PRQR or IXHL?

Is PRQR or IXHL more profitable?

Do institutionals & insiders have more ownership in PRQR or IXHL?

Does the media prefer PRQR or IXHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools